Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for the ...
This important study describes a first-in-human trial of autologous p63+ stem cells in patients with idiopathic pulmonary fibrosis, a lethal condition for which effective treatments are lacking. The ...
In their latest study published in Scientific Reports on November 18, 2024, they present a convincing proof-of-concept for a hybrid 'in silico/in-cell' controller (HISICC). The team's technology ...
China factory activity grows slightly more than expected Non-manufacturing growth stalls Economy may be turning a corner but US tariff threats cloud outlook BEIJING, Nov 30 (Reuters) - China's ...
A novel hydrovoltaic cell developed by researchers at the Chinese Academy of Sciences (CAS) can continuously generate electricity using little water and no sunlight. This feature could help deploy ...
It is expected to invest $138 million (about 999 million yuan) in the solar cell plant and $75 million (about 543 million yuan) in the solar module plant, which will mainly serve the local market, ...